Vivimed Labs Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: VIVIMEDLAB BSE: 532660
₹5.44
▼ -0.11 (-1.98%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
27/100
Weak
Valuation
—/100
Data unavailable
Momentum
13/100
Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Vivimed Labs Limited is an India-based global supplier of specialty chemicals and pharmaceuticals. Headquartered in Hyderabad, India. Vivimed is a manufacturer of active pharmaceutical ingredients, active ingredients for home and personal care, hair dyes, imaging chemicals and photochromics.

Source: Wikipedia

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
1.64%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
4.4
Relative return vs Sector, qtr %
-4.4
Free Cash Flow
₹8 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-138.10%
as of Dec. 31, 2025
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-452.09%
as of March 31, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-46.16%
as of March 31, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-3579.36%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-66.56%
as of March 31, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.37
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
-1.89
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-43.25
as of March 31, 2026
Industry median 10.58 (182 companies)
Net Margin
-1870.14%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-1859.66%
as of March 31, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-299.07%
as of March 31, 2026
Industry median 12.41% (182 companies)
Return on Assets
-23.28%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-56.02%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
83.30%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (-1.89)
  • Yes Return on equity is 15% or more (83.3%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

1 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 4 met
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.0%
Low 5.4400 · High 5.6500
1W return
1.5%
Low 5.3400 · High 5.7700
1M return
-21.5%
Low 5.2800 · High 6.8000
52W return
9.9%
Low 4.7500 · High 29.4000
Lifetime High ₹473.7500 (Jan. 8, 2016)
Lifetime Low ₹4.8800 (Aug. 10, 2026)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
5.5
10D
5.6
20D
5.7
50D
5.8
100D
6.2
200D
7.4

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

5.51
Pivot
First resistance5.58
Second resistance5.72
Third resistance5.79
First support5.37
Second support5.30
Third support5.16
Day RSI38.0
Day MFI31.6
Day MACD-0.15
Day MACD signal-0.08

Beta

1M-0.72
3M0.28
1Y0.56
3Y0.56

Price change analysis

↓ -21.5%
Over 1 Month
LowHigh
5.286.80
↓ -4.4%
Over 3 Months
LowHigh
4.757.21
↓ -1.6%
Over 6 Months
LowHigh
4.758.10
↑ 9.9%
Over 1 Year
LowHigh
4.7529.40
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (March 31, 2026)
₹8 Cr
Net profit (March 31, 2026)
₹-141 Cr
Basic EPS (March 31, 2026)
₹-17.1400

Ranks #None of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Mar 2026
  • Promoter7.57%
  • FII/FPI1.64%
  • Public90.79%

Largest holders

NameCategoryShares %Shares
KITARA PIIN 1102Public9.3700%7766387
VARALWAR SANDEEPPromoter2.8100%2327632
WILLIAM F HARVEYPublic1.6500%1369840
SAMEER MAHENDRA SAMPATPublic1.6400%1359165
SUBHASH VARALWARPromoter1.6300%1349154

As of March 31, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 7.77% to 7.57% in Mar 2026 qtr

Historical fii holding

FII/FPI holdings were unchanged at 1.64% in Mar 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.00% in Mar 2026 qtr

All shareholding details →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
20 Mar 2023 Santosh Varalwar Promoter Pledge Invoke 0 ₹25,708
24 Jun 2022 Santosh Varalwar Promoter Sell 0 ₹0
26 Apr 2022 Vithabai Varalwar Promoter Pledge Invoke 0 ₹19.00 L
26 Apr 2022 Sujatha Varalwar Promoter Pledge Invoke 0 ₹30.00 L
26 Apr 2022 Manohar Rao Varalwar Promoter Pledge Invoke 0 ₹5.20 L
4 Apr 2022 B B R PROJECTS PRIVATE LIMITED Promoter group Pledge Invoke 0 ₹8.62 L
24 Jan 2022 Santosh Varalwar Promoter Pledge Invoke 0 ₹30.83 L
24 Jan 2022 B B R PROJECTS PRIVATE LIMITED Promoter group Pledge Invoke 0 ₹15.71 L
24 Jan 2022 Santosh Varalwar Promoter Pledge Invoke 0 ₹1.56 L
10 Jun 2021 SANTOSH VARALWAR Promoter Pledge Invoke 0 —

All insider and SAST disclosures →

DateClientDealActionQuantityPriceExchange
10 Feb 2026 KRONE FINSTOCK PRIVATE LIMITED Bulk Sell 581,010 7.4100 NSE
10 Feb 2026 KRONE FINSTOCK PRIVATE LIMITED Bulk Buy 6,010 7.6800 NSE
20 Jan 2026 KAMAL JEET GUPTA Bulk Buy 430,000 8.1700 NSE
20 Jan 2026 KAMAL JEET GUPTA Bulk Sell 130,000 7.8200 NSE
3 Apr 2023 A AND S TRADELINK Bulk Buy 712,573 6.4200 NSE
21 Jun 2022 LUHARUKA MEDIA & INFRA LTD Bulk Sell 551,627 7.6600 NSE
25 Jan 2022 SBICAP TRUSTEE COMPANY LIMITED Bulk Sell 429,108 20.1400 NSE
7 May 2021 ALPHA LEON ENTERPRISES LLP Bulk Sell 1,034,806 28.4200 NSE
7 May 2021 ALPHA LEON ENTERPRISES LLP Bulk Buy 5 28.9300 NSE
6 May 2021 ALPHA LEON ENTERPRISES LLP Bulk Buy 824,216 27.7500 NSE

All bulk and block deals →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
17 Jul 2026 Financial Results Yes
30 May 2026 Board meeting Rescheduled —
30 May 2026 Financial Results Yes
28 May 2026 Financial Results Yes
13 Mar 2026 Financial Results Yes

Corporate Announcements

All 1 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
8 Sep 2026 Company Update Vivimed Labs Ltd - 532660 - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • High Return on Equity (83.3%)

Weaknesses

  • Thin net profit margin (-1870.1%)
  • Negative shareholder equity (Debt/Equity -1.89) -- accumulated losses exceed paid-in capital
  • Tight liquidity (Current Ratio 0.37)
  • Declining revenue YoY (-66.6%)
  • Declining profit YoY (-3579.4%)

Opportunities

Data unavailable.

Threats

  • Weak interest coverage (-43.3x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Vivimed Labs Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.